Qiagen (QGEN) was downgraded by Zacks Research from "hold" to "strong sell".
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System [Yahoo! Finance]
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
Immunoassay for Neurological Biomarkers Market Research 2026 - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030 [Yahoo! Finance]
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery